Full Text View
Tabular View
No Study Results Posted
Related Studies
SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)
This study is currently recruiting participants.
Verified July 2011 by Monash University

First Received on January 16, 2008.   Last Updated on July 19, 2011   History of Changes
Sponsor: Monash University
Collaborator: National Heart Foundation, Australia
Information provided by: Monash University
ClinicalTrials.gov Identifier: NCT00604006
  Purpose

Individuals who were apart of the investigators Screen-HF study (NCT00400257) whose BNP level are in the top quintile will be offered participation in this study. Participants will be randomised to receive either spironolactone or placebo for two years. Participants will then be monitored for indications of heart failure. It is anticipated that the medication will reduce the development of heart failure in this group.


Condition Intervention Phase
Heart Failure
 Drug: Spironolactone
Drug: Placebo
 Phase III

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)

Resource links provided by NLM:

MedlinePlus related topics: Heart Failure
Drug Information available for: Spironolactone
U.S. FDA Resources

Further study details as provided by Monash University:

Primary Outcome Measures:
  • Effectiveness of Spironolactone in preventing heart failure [ Time Frame: 1 year and 2 year ] [ Designated as safety issue: No ]
  • Cost effectiveness of Spironolactone prevention [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Development of evidence of LV dysfunction, either systolic or diastolic, on echocardiography and/or symptomatic heart failure [ Time Frame: 1 year and 2 year ] [ Designated as safety issue: No ]
  • Change in 6 minute walk test between the two groups [ Time Frame: 1 year and 2 years ] [ Designated as safety issue: No ]
  • Change in quality of life between the two groups [ Time Frame: 1 year and 2 year ] [ Designated as safety issue: No ]
  • Change in left ventricular remodelling parameters [ Time Frame: 1 year and 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 600
Study Start Date: September 2008
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A Drug: Spironolactone
25 mg tablets (placed in capsules for blinding) once daily.
Placebo Comparator: Group B Drug: Placebo
Placebo (lactose in capsules for blinding) once daily

  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Was recruited to SCREEN-HF
  2. Has provided informed consent

Exclusion Criteria:

  1. Uncorrected hyperkalaemia
  2. eGFR < 30 ml/min
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00604006

Contacts
Contact: Henry Krum, MBBS FRACP PhD +61 3 9903 0042 henry.krum@med.monash.edu.au

Locations
Australia, Victoria
Alfred Hospital Recruiting
Melbourne, Victoria, Australia, 3004
Contact: Henry Krum, MBBS FRACP PhD     +61 3 9903 0042     henry.krum@med.monash.edu.au    
Principal Investigator: Henry Krum, MBBS FRACP PhD            
Sub-Investigator: Chris Reid, A/Professor            
Sub-Investigator: Pupalan Iyngkaran, Doctor            
Sub-Investigator: Michele McGrady, Doctor            
Sponsors and Collaborators
Monash University
National Heart Foundation, Australia
Investigators
Principal Investigator: Henry Krum, MBBS FRACP PhD Monash University / Alfred Hospital
  More Information

No publications provided

Responsible Party: Prof Henry Krum, Monash University / Alfred Hospital
ClinicalTrials.gov Identifier: NCT00604006     History of Changes
Other Study ID Numbers: CP-02/07
Study First Received: January 16, 2008
Last Updated: July 19, 2011
Health Authority: Australia: Human Research Ethics Committee

Keywords provided by Monash University:
Prevention of heart failure in individuals at high risk

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Spironolactone
Aldosterone Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
 Physiological Effects of Drugs
Pharmacologic Actions
Diuretics
Natriuretic Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 12, 2012



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services